ProMIS Neurosciences Q2 net loss $10.1M; PRECISE-AD enrollment >50%, no ARIA; raised $21.6M in July

ProMIS Neurosciences Inc.

2025-Q2 EPS reported -$0.50 vs consensus -$4.42 ▲ beat (+88.7%)

Net loss $10.1M for Q2 2025 vs $2.6M a year ago; R&D spend $8.7M on PRECISE-AD trial.
Cash $4.5M at June 30; raised $21.6M gross proceeds in July via offerings and warrant exercises.
PRECISE-AD Phase 1b: over 50% of 128 patients enrolled; no ARIA or dropouts to date.
FDA granted Fast Track Designation for PMN310 in Alzheimer's disease in July 2025.
Company expects blinded interim results in 2Q 2026, final topline in 4Q 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.